Pall T. Onundarson: The Fiix Test Team Was Awarded UNIVANTS 2025!
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, proudly reposted from Eduardo Freggiaro on LinkedIn:
”The Fiix test team was awarded UNIVANTS 2025 Team of Distinction and got to meet the UNIVANTS of HealthCare Excellence executives at the ADLM (previously AACC) 2025 in Chicago.
The prize is awarded by 7 important healthcare associations around the world.
These people see the potential of improved patient care through replacing the conventional monitoring method of warfarin and VKAs (PT-INR) with a new test that more accurately reflects the antithrombotic effect, reduces anticoagulation variability and enhances effectiveness of anticoagulation with the old drug class that everybody had written off and thought they knew all about…
But now clinical pharmacology needs some revision.
Fortunately, it is very easy to replace the PT-INR with the Fiix-NR: same instruments, same staff, mostly the same dosing protocols.
The Fiix test is CE marked in Europe, still for scientific use elsewhere, manufactured by Hart Biologicals Limited in England.”
Eduardo Freggiaro, President of FBA, Executive Board member of IFCC, shared an honoring post on LinkedIn:
”During the ADLM congress in Chicago I had the opportunity and honor to participate in this photo with the winners of the highest recognition of the UNIVANTS 2025 award.
Also present were previous winners, Abbott executives and the CEO of the ADLM.
Congratulations to Professor Pall T. Onundarson, M.D. and his team for the excellent work they have done.”
Stay updated on the emerging with Hemostasis Today.
-
Aug 13, 2025, 09:21VELORA Discover Study Now Enrolling: Advancing Care for Type 1 Von Willebrand Disease
-
Aug 13, 2025, 06:44Chokri Ben Lamine: Causes and Diagnostic Approach to PTT Prolongation
-
Aug 13, 2025, 05:41ISTH 2025 Recorded Sessions Now Available on ISTH Academy
-
Aug 13, 2025, 01:39Radoslaw Kaczmarek: Challenges Limiting Gene Therapy Use in Hemophilia
-
Aug 12, 2025, 20:03David McIntosh Urges WHO, the European Blood Alliance, the International Plasma and Fractionation Association to Stop Opposition to VRCD
-
Aug 13, 2025, 16:24Giuseppe Lippi on Laboratory Diagnostics for Immediate Management of Acute Bleeding
-
Aug 13, 2025, 06:13Pip Nicolson: Understanding VITT From COVID-19 Vaccines
-
Aug 13, 2025, 05:23Baseline Hemoglobin Predicts Outcomes in Acute VTE: Low Hb Linked to Higher Bleeding, Ischemia and Mortality Risk
-
Aug 13, 2025, 04:13Lindsey George on Gene Therapy Transforming Hemophilia Care
-
Aug 13, 2025, 02:26Case Report Alert: Basilar Artery Occlusion in IgA-APS
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman
-
Aug 13, 2025, 10:25Joshua Muia on His HTRS Leadership Role Impact
-
Aug 11, 2025, 05:16Andreas Calatzis: Any Information on Soviet Thrombelastographs?
-
Aug 9, 2025, 15:36NBCA: Blood Clot Survivor Runs 2025 NYC Marathon with Team Stop the Clot
-
Aug 8, 2025, 18:33Hemophilia Alliance during Tennessee Hemophilia and Bleeding Disorders Foundation Annual Meeting 2025